Effectiveness and tolerability in people with narcolepsy transitioning from sodium oxybate to low-sodium oxybate: Data from the real-world TENOR study

被引:8
|
作者
Bae, Charles J. [1 ]
Zee, Phyllis C. [2 ]
Leary, Eileen B. [3 ]
Fuller, Douglas S. [4 ]
Macfadden, Wayne [4 ,6 ]
Candler, Shawn [4 ]
Steininger, Teresa L. [3 ]
Husain, Aatif M. [5 ]
机构
[1] Univ Penn, Penn Med, Philadelphia, PA USA
[2] Northwestern Univ, Feinberg Sch Med, Chicago, IL USA
[3] Jazz Pharmaceut, Palo Alto, CA USA
[4] Jazz Pharmaceut, Philadelphia, PA USA
[5] Duke Univ, Med Ctr, Durham, NC USA
[6] 2005 Market St, Philadelphia, PA 19103 USA
关键词
Narcolepsy; Excessive daytime sleepiness; Epworth Sleepiness Scale; Cataplexy; Sodium oxybate; Low -sodium oxybate; BLOOD-PRESSURE; WITHDRAWAL; BURDEN;
D O I
10.1016/j.sleep.2023.05.023
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objectives: The Transition Experience of persons with Narcolepsy taking Oxybate in the Real-world (TENOR) study was conducted to provide real-world insight into the experience of people with narcolepsy switching from sodium oxybate (SXB) to low-sodium oxybate (LXB; 92% less sodium than SXB). Methods: TENOR is a patient-centric, prospective, observational, virtual-format study. Participants were adults with narcolepsy (type 1 or 2) who were transitioning from SXB to LXB treatment (& PLUSMN;7 days from LXB initiation). Effectiveness and tolerability data were collected online from baseline (taking SXB) through 21 weeks (taking LXB) via daily and weekly diaries and questionnaires, including the Epworth Sleepiness Scale (ESS), the Functional Outcomes of Sleep Questionnaire, short version (FOSQ-10), and the British Columbia Cognitive Complaints Inventory (BC-CCI). Results: TENOR participants (N = 85) were 73% female with a mean (SD) age of 40.3 (13.0) years. Mean (SD) ESS scores decreased numerically throughout the transition from SXB to LXB (baseline: 9.9 [5.2]; week 21: 7.5 [4.7]), with 59.5% and 75.0% of participants having scores in the normal range (& LE;10) at baseline and week 21, respectively. Mean (SD) FOSQ-10 scores (baseline: 14.4 [3.4]; week 21: 15.2 [3.2]) and BC-CCI scores (baseline: 6.1 [4.4]; week 21: 5.0 [4.3]) also remained stable. The most common symptoms related to tolerability reported by participants at baseline were sleep inertia, hyperhidrosis, and dizziness (45.2%, 40.5%, and 27.4%, respectively), which decreased in prevalence by week 21 (33.8%, 13.2%, and 8.8%, respectively). Conclusions: Findings from TENOR confirm maintenance of effectiveness and tolerability when transitioning from SXB to LXB treatment. & COPY; 2023 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
引用
收藏
页码:65 / 74
页数:10
相关论文
共 50 条
  • [1] Effectiveness and tolerability in people with narcolepsy transitioning from sodium oxybate to low-sodium oxybate: Data from the real-world TENOR study (vol 109, pg 65, 2023)
    Bae, Charles J.
    Zee, Phyllis C.
    Leary, Eileen B.
    Fuller, Douglas S.
    Macfadden, Wayne
    Candler, Shawn
    Steininger, Teresa L.
    Husain, Aatif M.
    SLEEP MEDICINE, 2024, 119 : 17 - 18
  • [2] Dosing and transition characteristics in people with narcolepsy transitioning from sodium oxybate to low-sodium oxybate: Data from the real-world TENOR study
    Husain, Aatif M.
    Zee, Phyllis C.
    Leary, Eileen B.
    Fuller, Douglas S.
    Macfadden, Wayne
    Candler, Shawn
    Whalen, Marisa
    Bae, Charles J.
    SLEEP MEDICINE, 2024, 113 : 328 - 337
  • [3] EFFICACY AND SAFETY IN PEOPLE WITH NARCOLEPSY TRANSITIONING FROM SODIUM OXYBATE TO LOWER-SODIUM OXYBATE: DATA FROM THE REAL-WORLD TENOR STUDY
    Leary, Eileen
    Zee, Phyllis
    Fuller, Douglas
    Macfadden, Wayne
    Steininger, Teresa
    Bae, Charles
    Husain, Aatif
    SLEEP, 2022, 45 : A176 - A177
  • [4] DOSING AND REASONS FOR TRANSITIONING FROM SODIUM OXYBATE TO LOWER-SODIUM OXYBATE IN PEOPLE WITH NARCOLEPSY: DATA FROM THE REAL-WORLD TENOR STUDY
    Husain, Aatif
    Leary, Eileen
    Fuller, Douglas
    Macfadden, Wayne
    Whalen, Marisa
    Bae, Charles
    Zee, Phyllis
    SLEEP, 2022, 45 : A174 - A174
  • [5] INSIGHTS FROM REAL-WORLD AND INTERVENTIONAL STUDIES OF PATIENTS TRANSITIONING FROM SODIUM OXYBATE TO LOW-SODIUM OXYBATE
    Macfadden, W.
    Husain, A. M.
    Zee, P. C.
    Fuller, D. S.
    Candler, S.
    Bae, C.
    SLEEP MEDICINE, 2024, 115 : 219 - 219
  • [6] TREATMENT SATISFACTION AND PREFERENCES IN PEOPLE WITH NARCOLEPSY TRANSITIONING FROM SODIUM OXYBATE TO LOWER-SODIUM OXYBATE
    Bae, Charles
    Zee, Phyllis
    Leary, Eileen
    Macfadden, Wayne
    Fuller, Douglas
    Candler, Shawn
    Husain, Aatif
    SLEEP, 2023, 46 : A268 - A268
  • [7] Effectiveness and optimization of low-sodium oxybate in participants with narcolepsy switching from a high-sodium oxybate: data from the Substitution of Equal Grams of Uninterrupted Xyrem to Xywav study
    Macfadden, Wayne
    Leary, Eileen B.
    Fuller, Douglas S.
    Kirby, M. Todd
    Roy, Asim
    JOURNAL OF CLINICAL SLEEP MEDICINE, 2024, 20 (09): : 1467 - 1477
  • [8] PATIENT-REPORTED SLEEP QUALITY IN PEOPLE WITH NARCOLEPSY TRANSITIONING FROM SODIUM OXYBATE TO LOWER-SODIUM OXYBATE
    Husain, Aatif
    Zee, Phyllis
    Leary, Eileen
    Macfadden, Wayne
    Fuller, Douglas
    Candler, Shawn
    Bae, Charles
    SLEEP, 2023, 46
  • [9] Effectiveness and Optimization of Low-Sodium Oxybate in Participants With Narcolepsy Switching From High-Sodium Oxybate: Interim Data from the Substitution of Equal Grams of Uninterrupted Xyrem to Xywav (SEGUE) Study
    Leary, Eileen
    Kirby, Todd
    Skowronski, Roman
    Xu, Kevin
    Pfister, Craig
    Macfadden, Wayne
    NEUROLOGY, 2023, 100 (17)
  • [10] REAL-WORLD SAFETY AND EFFECTIVENESS OF SODIUM OXYBATE IN THE MANAGEMENT OF NARCOLEPSY: A SYSTEMATIC LITERATURE REVIEW
    Kandregula, N.
    Choletti, V
    Kalakota, C.
    Vullengala, N.
    Bhavanasai, S.
    Pesara, N. S.
    Udhayasri, R.
    Gomes, A.
    Dang, A.
    Dang, D.
    Vallish, B. N.
    VALUE IN HEALTH, 2023, 26 (12) : S505 - S505